rope01 rope02

Pipeline

Our internally developed pipeline of next-generation tyrosine kinase inhibitors (TKIs) target genetic drivers of cancer in both TKI-naïve and TKI-pretreated patients. We hold development and commercialization rights to our drug candidates in all regions expect repotrectinib in certain countries in Greater China.

Discovery

Preclinical

Early Stage
Clinical Development

Late Stage
Clinical Development

Regulatory Submission

Repotrectinib (ROS1/TRK)¹

TRIDENT-1: Advanced NSCLC (ROS1) and solid tumors (NTRK)
Late Stage - Clinical Development
Pediatric advanced solid tumors
Late Stage - Clinical Development
TRIDENT-2: KRAS-targeting combination
Preclinical

TPX-0022 (MET)²

SHIELD-1: Advanced solid tumors
Early Stage - Clinical Development
SHIELD-2: EGFR combination
Preclinical

TPX-0046 (RET)²

Advanced solid tumors
Early Stage - Clinical Development

TPX-0131 (ALK)²

Advanced NSCLC
Preclinical

Discovery Programs

Multiple Oncology Targets
Discovery

¹ Partnered with Zai Lab in Greater China; Turning Point retains worldwide rights outside of Greater China. ² Turning Point retains worldwide rights.